Edward A. O’Neill

6.4k total citations · 2 hit papers
91 papers, 4.7k citations indexed

About

Edward A. O’Neill is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Edward A. O’Neill has authored 91 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Molecular Biology, 42 papers in Endocrinology, Diabetes and Metabolism and 18 papers in Surgery. Recurrent topics in Edward A. O’Neill's work include Diabetes Treatment and Management (34 papers), Diabetes Management and Research (21 papers) and Melanoma and MAPK Pathways (18 papers). Edward A. O’Neill is often cited by papers focused on Diabetes Treatment and Management (34 papers), Diabetes Management and Research (21 papers) and Melanoma and MAPK Pathways (18 papers). Edward A. O’Neill collaborates with scholars based in United States, Japan and China. Edward A. O’Neill's co-authors include Thomas J. Kelly, Stephen J. O’Keefe, Michael J. Tocci, Randall L. Kincaid, Nicolas Mermod, Robert Tjian, Jun‐ichi Tamura, Betsy Frantz, Keith D. Kaufman and Philip J. Rosenfeld and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Edward A. O’Neill

90 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin

1992 760 citations Stephen J. O’Keefe, Jun‐ichi Tamura et al. Nature profile →
The proline-rich transcriptional activator of CTF/NF-I is distinct from the replication and DNA binding domain

1989 725 citations Nicolas Mermod, Edward A. O’Neill et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward A. O’Neill United States	30	2.9k	843	765	735	682	91	4.7k
David A. Ostrov United States	42	1.9k 0.6×	737 0.9×	340 0.4×	1.0k 1.4×	518 0.8×	141	5.1k
Mario R. Ehlers United States	33	1.7k 0.6×	565 0.7×	1.1k 1.5×	960 1.3×	1.2k 1.7×	77	4.6k
Pierre Formstecher France	35	2.4k 0.8×	481 0.6×	261 0.3×	459 0.6×	774 1.1×	114	3.9k
Jonathan M. Gibbins United Kingdom	48	2.1k 0.7×	374 0.4×	300 0.4×	1.1k 1.5×	668 1.0×	197	7.1k
Motowo Tomita Japan	40	2.7k 0.9×	597 0.7×	445 0.6×	1.2k 1.6×	585 0.9×	116	5.6k
Roger White United Kingdom	40	3.0k 1.0×	821 1.0×	408 0.5×	1.2k 1.6×	1.3k 1.9×	60	7.2k
Felicity E. B. May United Kingdom	43	2.4k 0.8×	1.2k 1.5×	630 0.8×	936 1.3×	1.1k 1.6×	103	4.7k
Dominique Lombardo France	38	2.7k 0.9×	1.0k 1.2×	624 0.8×	683 0.9×	619 0.9×	130	5.1k
Yoshiki Kawabe Japan	38	1.4k 0.5×	534 0.6×	659 0.9×	1.2k 1.7×	217 0.3×	119	4.4k
Reinhard Kofler Austria	49	4.1k 1.4×	1.2k 1.5×	590 0.8×	1.9k 2.5×	765 1.1×	141	6.9k

Countries citing papers authored by Edward A. O’Neill

Since Specialization

Citations

This map shows the geographic impact of Edward A. O’Neill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward A. O’Neill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward A. O’Neill more than expected).

Fields of papers citing papers by Edward A. O’Neill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward A. O’Neill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward A. O’Neill. The network helps show where Edward A. O’Neill may publish in the future.

Co-authorship network of co-authors of Edward A. O’Neill

This figure shows the co-authorship network connecting the top 25 collaborators of Edward A. O’Neill. A scholar is included among the top collaborators of Edward A. O’Neill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward A. O’Neill. Edward A. O’Neill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nussbaum, Jesse C., Azher Hussain, P. Butera, et al.. (2024). Single‐ and Multiple‐Dose Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, in Healthy Adults. The Journal of Clinical Pharmacology. 64(8). 1023–1029. 4 indexed citations

Seino, Yutaka, Kohei Kaku, Takashi Kadowaki, et al.. (2021). A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in J apanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. Diabetes Obesity and Metabolism. 23(6). 1342–1350. 3 indexed citations

Kadowaki, Takashi, Yutaka Seino, Kohei Kaku, et al.. (2021). A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. Diabetes Obesity and Metabolism. 23(6). 1242–1251. 4 indexed citations

Kaku, Kohei, Takashi Kadowaki, Yutaka Seino, et al.. (2021). Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes Obesity and Metabolism. 23(9). 2099–2108. 4 indexed citations

Gantz, Ira, Taro Okamoto, Yuka Ito, et al.. (2017). A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. Diabetes Therapy. 8(4). 793–810. 5 indexed citations

Xu, Lei, et al.. (2015). Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials. Diabetes Therapy. 6(1). 29–40. 8 indexed citations

Kaplan, Steven A., Jeannette Y. Lee, Edward A. O’Neill, Alan G. Meehan, & John W. Kusek. (2013). Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. The Aging Male. 16(4). 169–172. 40 indexed citations

Bays, Harold, Hilde Giezek, James M. McKenney, Edward A. O’Neill, & Andrew M. Tershakovec. (2012). Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus. Metabolic Syndrome and Related Disorders. 10(4). 260–266. 10 indexed citations

Girman, Cynthia J., Tzuyung D. Kou, Kimberly G. Brodovicz, et al.. (2011). Risk of acute renal failure in patients with Type 2 diabetes mellitus. Diabetic Medicine. 29(5). 614–621. 67 indexed citations

10.

Seck, Thomas, Yong Chen, Karl J. Krobot, et al.. (2010). Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double‐blind, non‐inferiority trial. Diabetes Obesity and Metabolism. 13(2). 160–168. 136 indexed citations

11.

Yu, Xiang‐Qing, et al.. (2010). Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate. Xenobiotica. 40(5). 350–356. 15 indexed citations

12.

Girman, Cynthia J., Tzuyung D. Kou, Charles M. Alexander, et al.. (2010). Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obesity and Metabolism. 12(9). 766–771. 161 indexed citations

13.

Natarajan, S., Luping Liu, James E. Thompson, et al.. (2006). p38 MAP kinase inhibitors. Part 5: Discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold. Bioorganic & Medicinal Chemistry Letters. 16(20). 5468–5471. 11 indexed citations

14.

Patel, Sangita B., et al.. (2003). Lattice stabilization and enhanced diffraction in human p38α crystals by protein engineering. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1696(1). 67–73. 37 indexed citations

15.

Chen, Jue, Daniel Ladd, Erguang Li, et al.. (1996). T cell responses in calcineurin A alpha-deficient mice.. The Journal of Experimental Medicine. 183(2). 413–420. 129 indexed citations

16.

Martin, Mary M., A.P. Timerman, Candace J. Sabers, et al.. (1995). A Novel FK506 Binding Protein Can Mediate the Immunosuppressive Effects of FK506 and Is Associated with the Cardiac Ryanodine Receptor. Journal of Biological Chemistry. 270(44). 26511–26522. 145 indexed citations

17.

O’Keefe, Stephen J., Jun‐ichi Tamura, Randall L. Kincaid, Michael J. Tocci, & Edward A. O’Neill. (1992). FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature. 357(6380). 692–694. 760 indexed citations breakdown →

18.

Mermod, Nicolas, Edward A. O’Neill, Thomas J. Kelly, & Robert Tjian. (1989). The proline-rich transcriptional activator of CTF/NF-I is distinct from the replication and DNA binding domain. Cell. 58(4). 741–753. 725 indexed citations breakdown →

19.

Kelly, Thomas J., et al.. (1987). Replication of adenovirus and SV40 chromosomes in vitro. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 317(1187). 429–438. 3 indexed citations

20.

Rosenfeld, Philip J., Edward A. O’Neill, Ronald J. Wides, & Thomas J. Kelly. (1987). Sequence-Specific Interactions Between Cellular DNA-Binding Proteins and the Adenovirus origin of DNA Replication. Molecular and Cellular Biology. 7(2). 875–886. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact